HBV News and Research

RSS

Mathematical model assesses efficacy, cost-effectiveness of screening strategies for HCV

It is currently recommended in Europe that screening for hepatitis C virus should target people at high risk of infection.

2 Jul 2018

Scientists find how immune system helps to clear HBV infection after treatment interruption

Scientists from Karolinska Institutet and Hannover Medical School have published two studies that provide insights into how the immune system responds and helps to clear a hepatitis B infection after treatment interruption.

17 May 2018

Phase 1/2 study evaluates safety, tolerability of multiple-ascending doses of ARO-HBV in hepatitis B patients

Arrowhead Pharmaceuticals Inc. today announced that it has dosed the first 3 hepatitis B virus patients in the multiple-ascending dose portion of its ongoing Phase 1/2 study of ARO-HBV, the company's third generation subcutaneously administered RNA interference therapeutic being developed as a potentially curative therapy for patients with chronic HBV infection.

14 May 2018

Many European countries lack comprehensive policy to eliminate viral hepatitis

Many European countries lack a comprehensive policy to eliminate viral hepatitis as a major public health threat, according to a patient group-based survey implemented in 25 countries.

18 Apr 2018

New, sensitive HBV assay may allow earlier detection of hepatocellular carcinoma

Chronic hepatitis B virus (HBV) can progress to cirrhosis and hepatocellular carcinoma (HCC). A study published in The Journal of Molecular Diagnostics describes a new HBV assay that offers advantages over currently used methods because it has the capability to detect closed circular DNA (cccDNA) in serum, single cells, and preserved tissue samples.

12 Apr 2018

4 in 10 cancers preventable by adopting simple lifestyle changes

In a new research that comes via the American Cancer Society, it has been seen that over 40 percent of all cancers and nearly one in two cancer deaths can be prevented by incorporating simple lifestyle changes in daily routines.

26 Nov 2017

Texas Biomedical Research Institute tests promising new treatment for HBV infection

Research at the Southwest National Primate Research Center on the campus of Texas Biomedical Research Institute helped advance a new treatment now in human trials for chronic hepatitis B virus (HBV) infection.

7 Nov 2017

Daily aspirin therapy linked to reduced risk of HBV‐related liver cancer

A new study presented this week at The Liver Meeting – held by the American Association for the Study of Liver Diseases – found that daily aspirin therapy was significantly associated with a reduced risk in hepatitis B virus‐related liver cancer.

20 Oct 2017

Report sheds light on global market for infectious disease immunoassays

Kalorama Information says that infectious disease immunoassays beat the IVD market and the overall IVD market in terms of revenue growth. Immunoassays are tests that are based on the binding of antibodies to antigens to identify the presence of a substance.

16 Oct 2017

Shortage of Hepatitis B vaccine - prioritization of vaccinations announced in UK

According to a recent announcement made by Public Health England, there is a global shortage of vaccines used against hepatitis B infection. This announcement is followed up by a “prioritisation guidance” which means that persons who are at greatest risk of getting hepatitis B are to be vaccinated on priority if they have not received the vaccine before.

7 Aug 2017

FDA approves new treatment for all HCV genotypes 1-6

The U.S. Food and Drug Administration today approved Mavyret (glecaprevir and pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including patients with moderate to severe kidney disease and those who are on dialysis.

3 Aug 2017

U.S. FDA approves updated labeling for pan-genotypic single tablet regimen for HCV/HIV co-infected patients

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved updated labeling for Epclusa (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV.

1 Aug 2017

World Hepatitis Day – gearing towards eliminating viral hepatitis by 2030

July 28th is marked as world hepatitis day. The world is united in elimination of viral hepatitis by 2030. The World Health Organization (WHO) has published new data from 28 countries today and shown that nearly 70% of the world hepatitis burden is borne by these countries.

27 Jul 2017

ECDC highlights need to scale-up efforts for eliminating viral hepatitis in Europe

An estimated 4.7 million Europeans are living with chronic hepatitis B and almost 4 million (3.9) with chronic hepatitis C infection.

26 Jul 2017

Princeton scientists test cell-culture system to aid study of HBV infections

Scientists from Princeton University's Department of Molecular Biology have successfully tested a cell-culture system that will allow researchers to perform laboratory-based studies of long-term hepatitis B virus (HBV) infections

25 Jul 2017

FDA approves fixed-dose combination tablet for treating adults with chronic hepatitis C

The U.S. Food and Drug Administration today approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis.

18 Jul 2017

Study estimates number of cancer deaths in China attributable to potentially modifiable risk factors

A new report finds more than half of all cancer deaths in men in 2013 in China and more than a third of those in women were attributable to a group of potentially modifiable risk factors: smoking, alcohol, nutrition, weight, physical activity, and infections.

6 Jul 2017

Survey finds wide variation in hepatitis B, C testing policy and practice across the EU/EEA

The survey results suggest a wide variation in existing national testing policy and practice when it comes to hepatitis B and C - with overall limited monitoring of testing, diagnosis, and treatment across EU/EEA Member States.

1 Jun 2017

Statins may provide favorable effects in patients with HBV- or HCV-related cirrhosis

Infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) can lead to cirrhosis as well as liver cancer. A Hepatology study from Taiwan has found that statins may provide benefits to patients with HBV- or HCV-related cirrhosis.

8 May 2017

Study reveals promising results for primary liver cancer patients treated with SIR-Spheres Y-90 resin microspheres

Patients with advanced or inoperable Hepatocellular Carcinoma (HCC) who usually received one or two treatments with liver-directed SIR-Spheres Y-90 resin microspheres in the 459-patient French SARAH study had similar survival compared to patients who received standard twice-daily systemic treatment with sorafenib, but with less than half the number and significantly fewer severe treatment-related adverse effects and significantly better Quality of Life, according to data presented here at The International Liver Congress™ 2017.

26 Apr 2017